

**COGSTATE ANNOUNCES APPOINTMENT OF JANE MCALOON
TO BOARD OF DIRECTORS**

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Jane McAloon as an Independent Non-Executive Director and, following release of the Appendix 4D Half Year Financial Report on 23 February 2017, Chair of the Audit & Compliance Committee of Cogstate Ltd.

Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as President, Governance and Group Company Secretary from 2013, having been Group Company Secretary from 2007. Prior to joining BHP Billiton in 2006, Jane was part of the executive team at AGL as Group Manager External and Regulatory Services and Group Company Secretary.

Jane is currently a Non-Executive Director of Healthscope Ltd and Energy Australia Pty Ltd.

Jane previously held various Australian State and Commonwealth Government positions, including Director General NSW Ministry of Energy and Utilities, Deputy Director General NSW Cabinet Office as well as senior executive roles in Rail, Land & Water Conservation and Forestry. She previously worked in private legal practice.

Jane has a Bachelor of Economics (Hons) & Bachelor of Laws from Monash University and Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Australian Institute of Company Directors.

"I am very pleased to be able to announce another tremendous addition to the Board of Cogstate" commented Mr. Martyn Myer AO, Chairman of Cogstate Limited. "The appointment of Jane McAloon will bring invaluable commercial expertise to our Board. On the back of the announcement last week in respect of the appointment of Dr Richard Mohs as an independent non-executive director of Cogstate with extensive neuro-science experience, we feel that these very different but complementary skill sets will further strengthen the leadership of Cogstate. The appointments continue the enhancement of Cogstate's leadership that includes the appointment of George Hunnewell and Frank Cheng in November 2016".

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated to simplifying the measurement of cognition in clinical trials, academic research and healthcare. Cogstate is a pioneer in commercialising rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for neuropsychological and functional assessments to drive higher quality outcome measures in clinical trials. Cogstate customers include the world's leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. For more information visit www.cogstate.com.

Investor contact:

Brad O'Connor

Cogstate Chief Executive Officer +613 9664 1300 or 0411 888 347 boconnor@cogstate.com